Study: Assessing the Financial Impact of the 340B Drug Pricing Program on Drug Manufacturers - 340B Matters
16376
post-template-default,single,single-post,postid-16376,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

17 Jul Study: Assessing the Financial Impact of the 340B Drug Pricing Program on Drug Manufacturers

The contract pharmacy program is critical for 340B hospitals to maintain and expand access to care for low-income and rural patients. Without their contract pharmacy benefit, hospitals would face difficulties maintaining the same level of care for patients in need, particularly Medicaid patients, rural populations, and patients who suffer from chronic and life-threatening conditions.

Link to full report: http://www.340bhealth.org/files/340B_Financial_Impact_7_17.pdf

Link to overview: http://www.340bhealth.org/files/340B_Financial_Impact_7_17_Overview.pdf

 

 

Want To Stay Up-To-Date On The Latest 340B News?